Supernus Pharmaceuticals (SUPN) schedules Q4 and full-year 2025 results call
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Supernus Pharmaceuticals, Inc. filed a Form 8-K to announce when it will release its next financial update. The company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
Management, including the President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec, will host a conference call and webcast on February 24, 2026 at 4:30 p.m. ET to discuss these results and answer questions. A live webcast and a 60-day replay will be available through the Investor Relations section of the company’s website.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices) | (Zip Code) | ||||||||||
Registrant’s telephone number, including area code: (301 ) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Exchange Act
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 12, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter of 2025 after the market closes on Tuesday, February 24, 2026. The Company will host a conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. E.T. to discuss its fourth quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | Description | ||||
| 99.1 | Press Release dated February 12, 2026 filed as an Exhibit pursuant to Item 2.02 hereof. | ||||
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. | ||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SUPERNUS PHARMACEUTICALS, INC. | ||||||||
| DATED: February 12, 2026 | By: | /s/ Timothy C. Dec | ||||||
| Timothy C. Dec Senior Vice President and Chief Financial Officer | ||||||||
3
Exhibit 99.1
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
ROCKVILLE, Md., February 12, 2026 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2025 financial and business results on Tuesday, February 24, 2026, at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its
subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When will Supernus Pharmaceuticals (SUPN) report Q4 and full-year 2025 results?
Supernus plans to report fourth quarter and full-year 2025 financial and business results after the market closes on Tuesday, February 24, 2026. The timing is paired with a same-day conference call led by senior management.
Will Supernus Pharmaceuticals (SUPN) host a conference call for its 2025 results?
Yes, Supernus will host a conference call and webcast on February 24, 2026 at 4:30 p.m. ET. President and CEO Jack Khattar and CFO Tim Dec will present results and then take questions from participants.
How can investors access the Supernus (SUPN) Q4 and 2025 earnings webcast?
A live webcast will be available in the Events & Presentations section of Supernus’s Investor Relations website at www.supernus.com/investors. Participants can also pre-register to receive a personalized dial-in number and conference code for the call.
Will a replay be available for the Supernus (SUPN) February 24, 2026 earnings call?
Yes, after the live call, a replay will be available on the Investor Relations section of Supernus’s website. The company states the webcast will remain accessible online for 60 days following the live event.
What does the February 12, 2026 Supernus (SUPN) 8-K primarily disclose?
The filing discloses the planned timing and logistics for Supernus’s fourth quarter and full year 2025 financial and business results. It also furnishes a press release as an exhibit, detailing the conference call date, time, webcast access, and replay availability.
Filing Exhibits & Attachments
4 documents
Supernus Pharma
NASDAQ:SUPN
SUPN Rankings
SUPN Latest News
SUPN Latest SEC Filings
SUPN Stock Data
2.86B
54.86M
4.23%
109.56%
8.56%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
ROCKVILLE